Literature DB >> 23645563

Expression of the chemokines CXCL12 and CX3CL1 and their receptors in human nerve sheath tumors.

Kirsten Hattermann1, Gu Li, Heinz-Hermann Hugo, Rolf Mentlein, H Maximilian Mehdorn, Janka Held-Feindt.   

Abstract

Peripheral nerve sheath tumors are in most cases slowly growing neoplasms that can be adequately cured by surgical resection. However, facing the risk of a neurosurgical intervention and the trend of multiple relapses of nerve sheath tumors the development of additional therapy strategies seems to be favourable, and therefore substantiated knowledge of molecular and cellular mechanisms in nerve sheath tumors should be achieved. Here, we firstly describe the expression of the chemokines CXCL12 (SDF-1) and CX3CL1 (fractalkine) and their respective receptors CXCR4, CXCR7 and CX3CR1 in different entities of human nerve sheath tumors and normal control tissues. Both ligands and their receptors are expressed in high to moderate levels on mRNA and protein level in benign and malignant nerve sheath tumors. While CXCL12 was mainly found in schwannoma cells (S100⁺) in situ, its receptor CXCR4 is also partly found on CD11b-positive macrophages / microglia and its alternative receptor CXCR7 is also expressed by endothelial cells and macrophages. CX3CL1 is expressed by parts of the schwannoma and endothelial cells, whereas its receptor CX3CR1 is expressed by nearly all tumor cells and macrophages, but not by endothelial cells. Taken together, we could show the presence of CXCL12 and CX3CL1 and their respective receptors in benign and malignant human nerve sheath tumors. Further investigations may show their functional role in health and disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23645563     DOI: 10.14670/HH-28.1337

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  3 in total

1.  Down regulation of Akirin-2 increases chemosensitivity in human glioblastomas more efficiently than Twist-1.

Authors:  Sebastian Krossa; Anne Dorothée Schmitt; Kirsten Hattermann; Jürgen Fritsch; Axel J Scheidig; Hubertus Maximilian Mehdorn; Janka Held-Feindt
Journal:  Oncotarget       Date:  2015-08-28

2.  CXCR4: A new player in vestibular schwannoma pathogenesis.

Authors:  Maria Breun; Alexandra Schwerdtfeger; Donato Daniel Martellotta; Almuth F Kessler; Jose M Perez; Camelia M Monoranu; Ralf-Ingo Ernestus; Cordula Matthies; Mario Löhr; Carsten Hagemann
Journal:  Oncotarget       Date:  2018-01-10

Review 3.  Biomarkers in Vestibular Schwannoma-Associated Hearing Loss.

Authors:  Luis Lassaletta; Miryam Calvino; Jose Manuel Morales-Puebla; Pablo Lapunzina; Lourdes Rodriguez-de la Rosa; Isabel Varela-Nieto; Victor Martinez-Glez
Journal:  Front Neurol       Date:  2019-09-18       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.